PsyBio Therapeutics CEO, Evan Levine, to Participate in Panel Discussion at the MedTech Innovation Conference on October 29th

·2 min read

OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 25, 2021 /CNW/ - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that Evan Levine, CEO and Chairman, has been invited to participate in a panel discussion at the MedTech Innovation Conference to be held at the AV Irvine in Irvine, California on October 28-29, 2021.

Psybio Therapeutics Corp. Logo (CNW Group/PsyBio Therapeutics Corp.)
Psybio Therapeutics Corp. Logo (CNW Group/PsyBio Therapeutics Corp.)

Panel Details:
'Innovation in Mental Health'
Thursday, October 29th at 10:40 am PT / 1:40 pm ET
Registration: here

For more information on the conference, or to schedule a one-on-one meeting with the PsyBio management team, please contact KCSA Strategic Communications at PsyBio@kcsa.com.

About PsyBio Therapeutics Corp.

PsyBio Therapeutics is an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a Bio Medicinal Chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring, specifically because they are already known to have an effect within the brain.

PsyBio makes no medical, treatment or health benefit claims about PsyBio's proposed products. The U.S. Food and Drug Administration ("FDA") or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA- approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio's performance and operations.

The TSX Venture Exchange ("TSXV") has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2021/25/c3244.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting